目的 探討維生素D₃片聯(lián)合格列美脲片治療2型糖尿病的臨床療效。方法 選取2016年2月-2017年1月在襄陽市中心醫(yī)院接受治療的2型糖尿病患者86例，依據(jù)治療方法差別分為對照組與治療組，每組各43例。對照組初始口服格列美脲片，1 mg/次，1次/d，根據(jù)血糖調(diào)整用藥，最大維持劑量不超過6 mg/d。治療組在對照組的基礎上口服維生素D₃片，1片/次，2次/d。兩組患者均治療4周。比較兩組治療前后臨床療效、血糖指標變化以及內(nèi)環(huán)境穩(wěn)態(tài)模型評估-β（HOMA-β）、HOMA-IR和25（OH）D₃水平。結(jié)果 治療后，對照組和治療組的總有效率分別為81.40%和95.35%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者空腹血糖（FPG）、餐后2 h血糖（2 h PG）、糖化血紅蛋白（HbAlc）及空腹胰島素（FINS）水平均顯著下降（P<0.05）；且治療組血糖指標變化水平顯著好于對照組（P<0.05）。治療后，兩組HOMA-β及25（OH）D₃水平顯著升高，并且HOMA-IR水平明顯降低，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組上述指標改善情況顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 維生素D₃片聯(lián)合格列美脲片治療2型糖尿病具有較好的臨床效果，可有效改善胰島素抵抗和提高敏感性，具有一定的臨床推廣應用價值。

Objective To investigate the clinical effect of Vitamin D₃ Tablets combined with Glimepiride Tablets in treatment of type 2 diabetes mellitus. Methods Patients (86 cases) with type 2 diabetes mellitus in Xiangyang Central Hospital from February 2016 to January 2017 were divided into control and treatment groups based on different treatments, and each group had 43 cases. Patients in the control group were po administered with Glimepiride Tablets, 1 mg/time, once daily, which was adjusted according to blood sugar, and the maximum maintenance dose did not exceed 6 mg/d. Patients in the treatment group were po administered with Vitamin D₃ Tablets on the basis of the control group, 1 tablet/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy, the changes of blood glucose indicators, and HOMA-β, HOMA-IR, and 25(OH)D₃ levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.40% and 95.35%, respectively, and there was difference between two groups (P < 0.05). After treatment, the FPG, 2 h PG, HbAlc and FINS levels two groups was significantly decreased (P < 0.05). And the changes of blood glucose indicators in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the HOMA-β and 25(OH)D₃ levels in two groups were significantly increased, but HOMA-IR level was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Vitamin D₃ Tablets combined with Glimepiride Tablets has good clinical effect in treatment of type 2 diabetes mellitus, and can effectively improve insulin resistance and sensitivity, which has a certain clinical application value.